Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note published on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on MRNS. Jefferies Financial Group reissued a “hold” rating and issued a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Cantor Fitzgerald restated an “overweight” rating and set a $4.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Royal Bank of Canada decreased their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday, October 25th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Finally, Truist Financial downgraded Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Nine research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Price Performance

MRNS opened at $0.31 on Monday. The company has a market capitalization of $17.10 million, a P/E ratio of -0.13 and a beta of 1.26. The firm’s fifty day moving average price is $1.15 and its two-hundred day moving average price is $1.29. Marinus Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $11.26.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. abrdn plc boosted its holdings in Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after purchasing an additional 1,578,329 shares during the period. Suvretta Capital Management LLC grew its position in Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after buying an additional 1,253,901 shares in the last quarter. Avoro Capital Advisors LLC grew its position in Marinus Pharmaceuticals by 31.4% during the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after buying an additional 990,607 shares in the last quarter. GSA Capital Partners LLP increased its stake in Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in Marinus Pharmaceuticals in the 2nd quarter valued at $813,000. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.